# Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

> **NCT04823403** · PHASE1 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 27 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04823403
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-11-13
- **Primary completion:** 2022-11-04
- **Final completion:** 2024-11
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04823403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04823403, "Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04823403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*